Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
NCT01945424 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244
Last updated 2020-02-12
Summary
The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes.
Conditions
- Pregnancy
- Influenza
Interventions
- BIOLOGICAL
-
Quadrivalent Influenza Vaccine (QIV)
No Intervention as part of this protocol
Sponsors & Collaborators
-
Sanofi Pasteur, a Sanofi Company
lead INDUSTRY
Principal Investigators
-
Clinical Sciences & Operations · Sanofi Pasteur, a Sanofi Company
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-08-16
- Primary Completion
- 2019-09-15
- Completion
- 2019-09-15
Countries
- United States
Study Locations
More Related Trials
-
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
NCT06134648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
NCT04754594 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
NCT07071558 ·Status: COMPLETED ·Phase: PHASE1
-
Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
NCT05639894 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
NCT05229068 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
NCT03674177 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of an Acellular DPT Vaccine During Pregnancy
NCT01445743 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
NCT00740155 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
NCT05886777 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
NCT05900154 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
NCT05997290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
NCT06251024 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
NCT03191383 ·Status: WITHDRAWN ·Phase: PHASE2
-
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
NCT00617344 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil
NCT03960385 ·Status: COMPLETED
-
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
NCT03529773 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
NCT04904549 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
NCT05842967 ·Status: COMPLETED ·Phase: PHASE3
-
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
NCT02266628 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
NCT04520659 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
NCT03502707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
NCT06573281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1